RT Journal Article
SR Electronic
A1 Parry, Nicola
T1 ODYSSEY COMBO II: Alirocumab Significantly Improves Cholesterol Levels in Patients with High CV Risk
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 27
SP 10
OP 11
DO 10.1177/155989771427003
UL http://mdc.sagepub.com/content/14/27/10.abstract
AB This articls presented results from the Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia trial [ODYSSEY COMBO II; NCT01644188]. This phase 3 trial showed that for patients with high cholesterol and existing or increased risk of cardiovascular disease, alirocumab significantly improved cholesterol levels as compared to ezetimibe, when added to regular statin therapy.